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ABSTRACT OF THESIS 
 
 
UTERINE CORPUS MALIGNANCIES IN APPALACHIA KENTUCKY: 
INCIDENCE, SURVIVAL AND RELATED HEALTH DISPARITIES  
 
Uterine cancer is the nation’s most common gynecologic malignancy but is 
understudied in the geographically and socioeconomically diverse state of Kentucky 
(KY). This study assessed the frequency, distribution, and survival of uterine corpus 
malignancies in KY, and specifically the differences between Appalachia (AP) and non-
Appalachia (NAP).  
This study utilizes SEER and Kentucky Cancer Registries to study uterine corpus 
malignancy between January 1, 2000 and December 31, 2014. The analysis looks at 
incidence between diagnoses in AP and NAP. Evaluation criteria includes: tumor 
histology (Type I, Type II, sarcoma, and mixed uterine malignancy), age, race, smoking 
status, stage at diagnosis, insurance status, and county of residence at diagnosis.  
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CHAPTER 1.  INTRODUCTION 
1.1 Background 
According to 2018 Surveillance Epidemiology and End Results (SEER) data, the 
state of Kentucky (KY) has the highest incidence and the highest death rate for female 
cancers in the United States (U.S.).1 Kentucky’s cancer woes are a result of a 
constellation of enduring social, economic, and healthcare access inequities. Eastern KY 
is in the heart of Central Appalachia, an area that is mountainous, mostly rural, and one 
of the nation’s most economically disadvantaged regions. It is also a population that is 
almost exclusively non-Hispanic white (95%).2 The high cancer burden in Appalachia 
has been repeatedly linked to widespread poverty and related societal mores, including: 
tobacco abuse, obesity and associated metabolic syndromes, lower levels of education, 
unemployment, and limited access to healthcare.3-5 Many of these factors are known to 
influence the development of corpus uterine cancers. 
Cancer of the uterine corpus is the most common malignancy of the female 
reproductive system and the fourth most common cancer in U.S. women. Over the past 
decade, the incidence of uterine cancer in the U.S. has steadily increased, creating a 
growing gap between the number of new corpus cancers versus new female 
malignancies.1,6 From 2008 to 2018, the magnitude of the incidence gap in KY was 
twice the national trend, with a 46% increase in corpus cancers compared to a 12% 
increase in new female cancers.1,6 The geographic distribution of these cancers is an 
important part in explaining the elevated incidence in KY. Before we can overcome the 
disparities affecting uterine cancer in Kentucky’s different geographic regions, we must 
first understand the chief contributing factors. 
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1.2 Objectives 
The principle objective of this retrospective cohort study is to utilize SEER and 
the Kentucky Cancer Registry to compare the frequency, distribution, and disease 
survival of uterine corpus malignancies in the U.S. and Kentucky, and examine the 
differences between Appalachian and non-Appalachian KY regions. Secondary study 
objectives include an analysis of factors that influence the outcome of uterine corpus 
malignancies, including histology, stage, age, race, cigarette smoking, insurance status, 
and geographic area of residence. 
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CHAPTER 2. METHODS 
2.1 Data Collection Approval 
The University of Kentucky Institutional Review Board approved an expedited 
protocol for this cohort study. All U.S. population incidence data were obtained from 
SEER registries, while Kentucky data were collected through the Kentucky Cancer 
Registry (KCR). All Kentucky acute care hospitals, freestanding treatment centers, non-
hospital pathology laboratories and physician offices are mandated to report cancer cases 
to KCR. Data from KCR is included in the National Cancer Institute’s SEER program 
and the Cancer in North America publication. The Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) guidelines were used in reporting 
the results of this study.7 
2.2 Eligibility Criteria 
Women are eligible for this study if they are age 20 years or older, have a 
pathologic diagnosis of a uterine corpus malignancy, and are diagnosed in either the 
SEER and/or KCR between January 1, 2000 and December 31, 2014. Abstracted KCR 
data includes Appalachia region, tumor histology, age, race, smoking status, stage at 
diagnosis, insurance status, and county of residence at time of diagnosis. Cases were 
excluded for the following reasons: failure to meet age criteria, incomplete data 
abstraction with diagnosis from death certificate only, non-invasive disease, malignant 
neoplasm not otherwise specified, uncommon histology, or non-uterine malignancy. 
2.3 Definition of Variables 
Uterine corpus malignancies are categorized into 4 groups according to tumor 
histology: Type I, Type II, sarcoma, and mixed uterine malignancy. Type I uterine cancer 
is defined as low-grade (grade 1 or 2), endometrioid, diploid, and hormone-receptor 
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positive. Type II uterine cancer is defined as high-grade endometrioid, non-endometrioid 
(serous, clear cell, undifferentiated), aneuploid, TP53-mutated, and hormone-receptor 
negative.8 Uterine sarcoma includes both homologous and heterologous mesenchymal 
tumors of the uterus.9,10 Mixed uterine malignancies include both carcinomatous and 
sarcomatous components, and are alternatively named carcinosarcoma or malignant 
mixed Mullerian tumor (MMMT).10-12 
Uterine corpus malignancy diagnoses in Appalachian KY counties (AP) were 
compared to uterine corpus malignancy diagnoses in non-Appalachian KY counties 
(NAP). In 1965, the Congress of the Commonwealth of Kentucky designated 54 of KY’s 
120 counties as Appalachia. The economic growth and development of these counties is 
overseen by the Appalachian Regional Commission.4 Demographic data, type of uterine 
malignancy, and AP and NAP region are analyzed. Further county-specific analysis is 
performed to screen for clustering of cases in specific geographic regions. 
2.4 Statistical Analysis 
Age-adjusted cancer incidence is calculated for SEER, KY, AP, and NAP 
standardized by the U.S. 2000 population. Rate ratio test is used to decide the statistical 
significance of cancer incidence rates between SEER (excluding KY) and KY, AP and 
NAP.13 Descriptive analyses for demographics and clinical factors and bivariate analyses 
by AP and NAP are performed. Chi-square tests are used to examine the association 
between Appalachian status and histology types and other covariates.  Kaplan-Meier plot 
and Log-Rank test survival analyses are conducted to examine characteristics of 
histology and Appalachian status. Cox regression analysis is performed to identify which 
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demographics and clinical factors are associated with survival while controlling for other 
factors. All analyses are performed by SAS Statistical software version 9.4 (SAS 
Institute, Inc., Cary, NC). US cancer survival information is calculated based on 
SEER*Stat 8.3.5 (https://seer.cancer.gov/seerstat/). All statistical tests are two-sided with 
a 0.05 level of statistical significance. 
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CHAPTER 3. RESULTS 
3.1 Overview 
Between the years of 2000 to 2014, we identified 165,713 uterine corpus 
malignancies in SEER, and 8,948 in the KCR. The overall age–adjusted incidence rates 
are similar for US and KY populations; however, types and distribution differ. Compared 
to the US population, the incidence in KY is higher for Type I, but lower for Type II, 
sarcoma, and mixed malignancies (Table 3.1). For Kentucky women, the age-adjusted 
incidence of corpus cancers is significantly higher in AP compared to NAP counties (37.8 
vs. 31.5; P < .0001, Table 3.2). Type I malignancies were 6-7 fold more common than 
Type II, which had the second highest incidence. Specifically, AP has a higher incidence 
of Type I (P < .0001) and mixed malignancy (P = .04), while Type II and sarcoma are of 
similar incidence in AP and NAP counties (Table 2). A comparison of demographics by 
type of uterine malignancy is summarized in Table 3.3. Type I (79.3%) is the most 
common uterine corpus malignancy, followed by Type II (12.6%), mixed (4.2%), and 
sarcoma (3.9%). The mean age is significantly lower for sarcoma and Type I compared to 
Type II and mixed malignancies (P < .0001). A summary of all uterine cancer 
demographics by KY region is shown in Table 3.4. In addition to a higher age-adjusted 
incidence of Type I and mixed malignancy, AP compared to NAP counties have a 
younger age at diagnosis, larger NHW population, and fewer smokers. In addition, the 
AP cohort has more uninsured and Medicaid recipients, while NAP has a higher 
percentage of privately insured. 
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3.2 Incidence 
The overall age–adjusted incidence rate for uterine corpus cancer diagnosed from 
2000-2014 is the same for KY and US populations at 33.49 and 33.29 per 100,000, 
respectively (P = .51). Compared to uterine malignancies in the US, KY has a higher 
incidence of Type I (P = .03), but a lower incidence of Type II (P = .003), sarcoma (P = 
.0063), and mixed uterine malignancies (P < .001). In KY, the age-adjusted incidence rate 
per 100,000 women is as follows: Type I, 26.44; Type II, 4.15; sarcoma, 1.36; and mixed, 
1.35. Nearly one third of all KY uterine malignancies are diagnosed in women from AP 
counties (2,899 of 8,948). The age-adjusted incidence of uterine corpus malignancies in 
AP is significantly higher compared to NAP (37.76 vs. 31.53), a consequence of more 
Type I (P < .0001) and mixed malignancies (P = .04). In addition, the incidence of Type I 
and Type II cancers in Kentucky has continued to rise each of the last five years.  
3.3 Survival 
The overall survival for uterine corpus malignancy is similar for US and KY 
populations (Figure 1, P = .2415), and there is no difference when evaluated by specific 
histology. In both populations, survival is better for Type I and worse for Type II, 
sarcoma and mixed malignancy.  
On Kaplan-Meier analysis, KY women with Type I uterine cancer have the 
highest probability of survival, while mixed tumors have the lowest (Figure 2, P < 
.0001). These survival outcomes persist even when controlled for smoking status and 
race, and are similar in both AP and NAP counties (Χ2 = 303, p<0.0001; Χ2 = 680, P < 
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.0001, respectively). Whether comparing all corpus malignancy as one group or as 
individual types, there is no survival difference between AP and NAP counties (P = .47).  
On Cox regression analysis (Table 3.5), the hazard ratio for death (HR) is lowest 
for Type I (HR 0.655; 95% CI 0.547-0.783) and Type II cancers (HR 0.652; 95% CI 
0.538-0.791) compared to mixed malignancies (HR 0.926; 95% CI 0.764-1.21) and 
sarcoma (reference). This finding is independent of geographic region. Women from AP 
have similar survival compared to NAP (HR 0.896; 95% CI 0.795-1.009). Younger (20-
50 years) and middle aged (51-64 years) women have a significantly lower HR than 
women 65 years and older (P < .001). Nonsmokers have better overall survival than 
smokers, regardless of AP versus NAP region. Increasing grade and stage are associated 
with lower survival (P < .001). In AP, women with Medicaid (HR 1.67; 95% CI 1.14-
2.44) and Medicare (HR 1.54; 95% 1.05-2.26) insurance have an increased risk of death. 
3.4 Age 
The mean age at diagnosis for Type I uterine corpus malignancies is younger in 
AP versus NAP counties (59.4 vs. 60.7 years, P < .0001); likewise, women with mixed 
uterine tumors are diagnosed at a younger age in AP counties (65.4 vs. 68.4, P = .02). 
There are no observed differences in mean age at diagnosis for Type II or sarcoma 
malignancies. Over half of the Type II cancers are diagnosed in women over the age of 
65, and this is consistent in both AP and NAP regions. Women diagnosed with uterine 
sarcomas are evenly distributed between age groups in both regions. On Cox regression 
analysis, young age at diagnosis is an independent predictor of better survival for age 20-
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50 years (HR 0.29; 95% CI 0.25-0.35) and 51-64 years (HR 0.56; 95% CI 0.50-0.63) 
compared to over 65 years (Table 3.5) 
3.5 Race 
Each histology has a significantly higher proportion of Non-Hispanic Whites 
(NHW) compared to Non-Hispanic Blacks (NHB) (P < .0001). In AP counties, the 
percentage of NHW women by histology is as follows: 99% Type I, 98% Type II, 97% 
mixed, and 97% sarcoma. In NAP counties, NHB women are diagnosed with 5%, 13%, 
16%, and 16% Type I, Type II, mixed, and sarcoma, respectively. Overall, NHW have a 
higher probability of survival compared to NHB or other race (Χ2  = 64, P < .0001). NHW 
smokers and non-smokers both have higher overall survival compared to NHB (Χ2 = 38, 
P < .0001; Χ2 = 14, P = .003, respectively). On Kaplan-Meier survival estimate, NHB 
have significantly worse survival than NHW (Figure 3.3, P < .0001); however, after 
controlling for individual factors on Cox regression analysis, race is not a significant 
independent variable for the entirety of KY (Table 3.5), or in AP and NAP regions (P = 
.24). 
3.6 Smoking 
For the overall study population, 55% are nonsmokers, 24% are smokers, and the 
smoking status is unknown for 21%. Smokers with a uterine corpus malignancy have 
inferior survival compared to nonsmokers or those with unknown smoking status (Χ2 = 
34, P < .0001). There are fewer smokers in AP compared to NAP counties (Table 3.4, P 
= .002). For women diagnosed with uterine corpus cancers, the AP cohort is less likely to 
smoke for Type I (P = .005) and Type II (P = .083) cancers, though the later didn’t reach 
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statistical significance. There are no significant smoking associations between regions for 
mixed malignancies. Interpretation of the sarcoma group is confounded by a relative 
large number of unknown results compared to other histology groups. Smoking is 
associated with a worse survival on Cox multivariate regression analysis (HR 1.2; 95% 
CI 1.10-1.31. Table 3.5). 
3.7 Insurance 
Insurance coverage for women with uterine corpus malignancy differs across all 
four histologic types. Women from AP compared to NAP counties with Type I and Type 
II cancers are more likely to be uninsured or receive Medicaid assistance, while more 
women from NAP counties are privately insured (P < .001, P = .003, respectively). There 
are a similar percentage of uninsured cases for mixed tumors and sarcoma. Mixed cancers 
in NAP are more likely to have private insurance or Medicare compared to AP cases who 
receive Medicaid (P = .017). For uterine sarcoma, over 50% of NAP have private 
insurance, while the highest percentage in AP is Medicare (41.3%). Similar to the trend 
seen for all corpus malignancies, AP sarcomas have at least twice the number of 
Medicaid recipients compared to NAP counties (15.2% v 7.5%). On Cox regression 
analysis (Table 3.5), private insurance in KY is an independent predictor of better 
survival compared to no insurance (HR 0.57; 95% CI 0.47-0.69). More specifically, 
Medicaid or Medicare is associated with worse survival in AP, while private insurance is 
an independent predictor of better survival in NAP (HR 0.48; 95% CI 0.38-0.60). 
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3.8 Stage 
Information regarding stage is challenging to interpret because of changing 
treatment trends over the last decade. Since it doesn’t appear to alter survival, many low 
risk Type I uterine cancers do not undergo formal staging lymphadenectomy. Overall, 
stage I and II combined were of similar percentage between AP and NAP regions. The 
stage at diagnosis for sarcomas was unknown for the majority of cases; therefore, a 
reliable comparison cannot be made. There is a high number of unknown stages for 
mixed uterine malignancies as well; however, the percentage of advanced stage diagnoses 
in AP is double the rate recorded for NAP (P = .019). 
3.9 Incidence by County 
For Type I uterine cancer, the highest incidence is seen in 3 NAP compared to 7 
AP counties (33.37 to 45.28 cases per 100,000 people, Figure 3.4). In addition, 9 other 
AP counties are identified in the second highest incidence group compared to 3 NAP 
counties. Similarly, for Type II histology 2 NAP counties and 10 AP counties have the 
highest incidence (7.92-12.79 per 100,000). For mixed and sarcoma, the highest 
incidence counties are more evenly distributed between AP and NAP counties. For mixed 
malignancies, there are 2 NAP and 3 AP counties (3.78-6.78 cases per 100,000), and for 
sarcoma there is 1 NAP and 2 AP counties (4.87-9.64 per 100,000). 
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Table 3.1 Age-Adjusted Cancer Incidence for Uterine malignancy, U.S. vs Kentucky, 
2000-2014 
    
 
  N 
Age-adjusted 
Rate* 
Lower 95% 
CI 
Upper 95% 
CI 
P-Value 
All- US 165,713 33.49 33.33 33.66 
.5063 
All- KY 8,948 33.29 32.59 33.99 
Type 1- US 127,257 25.69 25.55 25.83 
.0274 
Type 1- KY 7,100 26.44 25.82 27.07 
Type 2- US 22,463 4.53 4.47 4.59 
.0027 
Type 2- KY 1,127 4.15 3.90 4.40 
Sarcoma- US 7,538 1.57 1.54 1.61 
.0063 
Sarcoma- KY 347 1.36 1.22 1.51 
Mixed- US 8,455 1.70 1.67 1.74 
< .0001 
Mixed - KY 374 1.35 1.21 1.49 
Comparison between SEER (U.S.) and KCR (KY), 2000-2014. 
*Age-adjusted Rate is per 100,000.  
Rate-ratio test for statistical comparison.  
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Table 3.2 Age-Adjusted Cancer Incidence for Uterine Malignancy in Kentucky, Non-
Appalachia vs Appalachia, 2000-1014 (N=8,948) 
  N 
Age-adjusted 
Rate* 
Lower 95% 
CI 
Upper 95% 
CI 
P-Value 
All- KY         <  .0001 
NAP 6049 31.53 30.73 32.34 
AP 2899 37.76 36.37 39.18 
Type 1         < .0001 
NAP 4764 24.86 24.16 25.59 
AP 2336 30.41 29.17 31.69 
Type 2         .1212 
NAP 781 4.02 3.74 4.32 
AP 346 4.46 4.00 4.96 
Sarcoma         .5836 
NAP 255 1.39 1.22 1.57 
AP 92 1.30 1.04 1.60 
Mixed Tumor         .0452 
NAP 249 1.25 1.10 1.42 
AP 125 1.58 1.32 1.89 
*Age-adjusted Rate is per 100,000. NAP- Non-Appalachia KY, AP- Appalachia KY.  
Chi square test for statistical comparison. 
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Table 3.3 Comparison of Demographics by Type of Uterine Malignancy in Kentucky, 
2000-2014 (N=8,948). 
 Type I Type II Sarcoma Mixed P-
Value   N % N % N % N % 
Total 7100 79.35% 1127 12.59% 347 3.88% 374 4.18%   
Age         <.0001 
Mean 60.38±12.59 65.23±12.69 56.73±14.07 67.38±11.45   
20-50 1406 19.80% 138 12.24% 125 36.02% 24 6.42%   
51-64 3170 44.65% 397 35.23% 119 34.29% 129 34.49%   
65+ 2524 35.55% 592 52.53% 103 29.68% 221 59.09%   
Race         <.0001 
White 6771 95.37% 1010 89.62% 302 87.03% 329 87.97%   
Black 269 3.79% 110 9.76% 43 12.39% 43 11.50%   
Other 31 0.44% 5 0.44% 1 0.29% 1 0.27%   
Unknown 29 0.41% 2 0.18% 1 0.29% 1 0.27%   
Hispanic         .4807 
Non-
Hispanic 
6913 97.37% 1105 98.05% 340 97.98% 366 97.86%   
Hispanic 32 0.45% 60 5.32% 2 0.58% 3 0.80%   
Unknown 155 2.18% 16 1.42% 5 1.44% 5 1.34%   
Marital         <.0001 
Never 
married 
950 13.38% 137 12.16% 49 14.12% 43 11.50%   
Ever 
Married 
3759 52.94% 518 45.96% 181 52.16% 172 45.99%   
Divorced 
or 
Widowed 
1704 24.00% 384 34.07% 87 25.07% 125 33.42%   
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Table 3.3 (continued) 
Unknown 687 9.68% 88 7.81% 30 8.65% 34 9.09%   
Smoke         .0017 
Non-
Smoker 
3982 56.08% 592 52.53% 168 48.41% 199 53.21%   
Smoker 1637 23.06% 284 25.20% 110 31.70% 103 27.54%   
Unknown 1481 20.86% 251 22.27% 69 19.88% 72 19.25%   
Insurance         <.0001 
Not 
Insured 
335 4.72% 46 4.08% 21 6.05% 20 5.35%   
Private 
Insured  
3177 44.75% 399 35.40% 170 48.99% 99 26.47%   
Medicare 2707 38.13% 560 49.69% 111 31.99% 214 57.22%   
Medicaid 538 7.58% 80 7.10% 33 9.51% 32 8.56%   
Other 
Public 
71 1.00% 7 0.62% 3 0.86% 2 0.53%   
Unknown 272 3.83% 35 3.11% 9 2.59% 7 1.87%   
Stage         <.0001 
In situ 6 0.08%   1 0.29%     
Stage I 5311 74.80% 541 48.00% 11 3.17% 60 16.04%   
Stage II 425 5.99% 106 9.41% 3 0.86% 16 4.28%   
Stage III 503 7.08% 237 21.03% 1 0.29% 37 9.89%   
Stage IV 251 3.54% 153 13.58% 3 0.86% 48 12.83%   
Unknown 604 8.51% 90 7.99% 328 94.52% 213 56.95%   
Chi square test for statistical comparison. 
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Table 3.4 Comparison of Demographics by Region for Uterine Malignancy in Kentucky, 
2000-2014 (N=8,948). 
  Total  NAP AP P-Value 
  N % N % N %   
Total 8948 100.00% 6049 67.60% 2899 32.40%   
Age 
      
.0023 
20-50 1693 18.92% 1108 18.32% 585 20.18%   
51-64 3815 42.64% 2543 42.04% 1272 43.88%   
65+ 3440 38.44% 2398 39.64% 1042 35.94%   
Mean 61.14±12.81 61.56±12.86 60.25±12.67 .3549 
Race 
      
< .0001 
White 8412 94.01% 5555 91.83% 2857 98.55%   
Black 465 5.20% 434 7.17% 31 1.07%   
Other 38 0.42% 36 0.60% 2 0.07%   
Unknown 33 0.37% 24 0.40% 9 0.31%   
Hispanic 
      
.0139 
Non-Hispanic 8724 97.50% 5890 97.37% 2834 97.76%   
Hispanic 43 0.48% 38 0.63% 5 0.17%   
Unknown 181 2.02% 121 2.00% 60 2.07%   
Marital 
      
< .0001 
Never married 1179 13.18% 876 14.48% 303 10.45%   
Ever Married 4630 51.74% 3073 50.80% 1557 53.71%   
Divorced/Widowed 2300 25.70% 1586 26.22% 714 24.63%   
Unknown 839 9.38% 514 8.50% 325 11.21%   
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Table 3.4 (continued) 
Smoke 
      
.002 
Non-Smoker 4941 55.22% 3287 54.34% 1654 57.05%   
Smoker 2134 23.85% 1509 24.95% 625 21.56%   
Unknown 1873 20.93% 1253 20.71% 620 21.39%   
Insurance 
      
< .0001 
Not Insured 422 4.72% 256 4.23% 166 5.73%   
Private Insured  3845 42.97% 2814 46.52% 1031 35.56%   
Medicare 3592 40.14% 2403 39.73% 1189 41.01%   
Medicaid 683 7.63% 309 5.11% 374 12.90%   
Other Public 83 0.93% 59 0.98% 24 0.83%   
Unknown 323 3.61% 208 3.44% 115 3.97%   
Stage 
      
< .0001 
In situ 7 0.08% 3 0.05% 4 0.14%   
Stage I 5923 66.19% 4026 66.56% 1897 65.44%   
Stage II 550 6.15% 341 5.64% 209 7.21%   
Stage III 778 8.69% 556 9.19% 222 7.66%   
Stage IV 455 5.08% 318 5.26% 137 4.73%   
N/A 558 6.24% 407 6.73% 151 5.21%   
Unknown 677 7.57% 398 6.58% 279 9.62%   
Histology 
      
.0466 
Type I 7100 79.35% 4764 78.76% 2336 80.58%   
Type II 1127 12.59% 781 12.91% 346 11.94%   
Sarcoma 347 3.88% 255 4.22% 92 3.17%   
Mixed 374 4.18% 249 4.12% 125 4.31%   
NAP- Non-Appalachia KY, AP- Appalachia KY.  
Chi square test for statistical comparison. 
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Table 3.5 Cox Regression Survival Analysis, Kentucky. 2000-2014.  
 
HR 95% CI P-Value 
Histology 
   
< .001 
Type I 0.655 0.547 0.783   
Type II 0.652 0.538 0.791   
Mixed 0.926 0.764 1.121   
Sarcoma ref 
  
  
Age 
   
< .001 
20-50 0.294 0.249 0.348   
51-64 0.564 0.501 0.634   
65+ ref 
  
  
Race 
   
.2435 
Black 1.080 0.936 1.254   
Other 0.852 0.424 1.711   
Unknown 0.186 0.026 1.322   
White 
   
  
Region 
   
.0687 
Appalachia 0.896 0.795 1.0090   
Non-Appalachia ref 
  
  
Cigarette Smoking 
   
< .001 
Smoker 1.201 1.100 1.310   
Unknown 1.125 1.027 1.232   
Non-Smoker ref 
  
  
Insurance 
   
< .001 
Medicaid 1.063 0.852 1.326   
Medicare 0.016 0.827 1.247   
Other Public 0.685 0.412 1.139   
Private Insured  0.568 0.469 0.689   
Unknown 0.846 0.655 1.092   
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Table 3.5 (continued) 
Not Insured ref 
  
  
Stage 
   
< .001 
In situ 0.449 0.063 3.197   
Stage II 1.669 1.440 1.934   
Stage III 2.645 2.356 2.969   
Stage IV 7.457 6.586 8.444   
Unknown 2.236 1.989 2.513   
Stage I ref 
  
  
Grade 
   
< .001 
Unknown 2.096 1.839 2.388   
2  1.168 1.049 1.301   
3  1.887 1.677 2.123   
Undifferentiated 2.211 1.910 2.560   
1 ref 
  
  
High School Education  
   
.0002 
High 0.781 0.665 0.916   
Low 0.788 0.697 0.890   
Moderate 0.885 0.772 1.015   
Very Low ref       
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Figure 3.1 Kaplan-Meier Survival Estimate from SEER data comparing the U.S. to 
Kentucky 2000-2014 (p=0.2415) 
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Figure 3.2 Kaplan-Meier Survival Estimate by Type of Uterine Malignancy for 
Kentucky, 2000-2014 (p<0.0001)  
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Figure 3.3 Kaplan-Meier Survival Estimate by Race for Kentucky, 2000-2014 
(p<0.0001).  
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Figure 3.4 Incidence of Type I Uterine Malignancy by Kentucky Region, 2000-2014. 
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CHAPTER 4. DISCUSSION 
Kentucky leads the nation in female cancer incidence and mortality. Similar to US 
trends, the incidence of uterine malignancy in KY is steadily increasing; however, it 
varies significantly based on geographic region and cancer type. Uterine corpus cancers 
in AP compared to NAP KY are different in cause and consequence. There are several 
relevant socioeconomic factors, including: age, obesity, cigarette smoking, race, 
insurance, and perhaps hereditary syndromes. Further characterizing these factors and 
understanding how they influence the cause and outcome of corpus cancers is important, 
particularly in Appalachia KY where the cancer burden is disproportionately high. 
4.1 Commentary on Results 
Compared to the rest of the nation, Type I uterine cancers are significantly more 
common in KY while other types of corpus cancers are less common. Our findings also 
show that Type I cancer in KY is more commonly a disease of younger, non-smoking, 
non-Hispanic white (NHW) women. Appalachia has a much higher incidence of corpus 
malignancies than NAP KY, and the numbers are particularly disproportionate given the 
population distribution in the state. While AP counties are home to 26.4% of Kentucky’s 
population, 32.4% of the uterine cancers come from this geographic region.2 In addition 
to Type I cancers, the age-adjusted incidence of mixed uterine malignancies is higher and 
the mean age at diagnosis is lower in AP compared to NAP counties. Although more 
cancer in younger women is an alarming trend, we did observe that younger women have 
improved survival regardless of geographic location.  
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Cancer outcomes are not always inferior for those living in socioeconomically 
disadvantaged regions like AP.14 Although the incidence of uterine cancers was higher in 
AP versus NAP counties, cancer-specific survival did not differ based on geographic 
location. This may reflect a balance of influences on survival, for instance: more cancers 
in AP but younger age at diagnosis, or fewer cancers in NAP but more cigarette smokers. 
For this investigation, the most likely explanation is the high percentage of Type I 
cancers relative to other types of uterine malignancy. Not only do Type I cancers make 
up 79% of the study population, they also have the highest survival, followed in order by 
Type II, sarcoma, and mixed malignancies.  
The prevalence of cigarette smokers in Kentucky remains the highest in the 
nation.1 Nearly 1 in 4 Kentucky residents smokes cigarettes (26%), contributing to the 
high number of lung, head and neck, and other smoking-attributable cancers.5 But for 
Type I uterine corpus cancers, cigarette smoking appears to be protective, possibly 
through an increase in progesterone receptor expression.15 A recent meta-analysis 
confirmed an inverse relationship between current and past cigarette smoking and the risk 
of endometrial cancer (RR=0.81; OR=0.72), especially in postmenopausal women.16 In 
this investigation, we observed that there are fewer cigarette smokers in AP than in NAP 
KY; though causation cannot be inferred, this may influence the higher incidence of Type 
I cancers in this geographic region. 
Uterine malignancy has historically been a disease of older women, but this is no 
longer the case. Findings from this investigation show that women from AP KY are being 
diagnosed with Type I and mixed uterine tumors at younger age. A recent pooled analysis 
of 24 studies found the mean age at diagnosis for Type I uterine corpus cancers is 61.9 
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years.17 In KY, women are being diagnosed with Type I uterine corpus cancers at a 
younger age, especially in AP compared to NAP counties (59.4 vs. 60.7 years, 
respectively; P < .0001). Interestingly, this trend is counter to the general KY population 
which is actually older in AP counties. The 2011-2015 American Community Survey 
reports a mean age in AP compared to NAP of 40.8 and 38.1 years, respectively.2 The 
same trend toward younger age at diagnosis is observed for mixed tumors in AP versus 
NAP KY (65.4 vs. 68.4 years, respectively; P = .02). In AP counties, 67% of Type I 
cancers are diagnosed in the age groups from 20-50 and 51-64 years compared to 63% 
for NAP KY, and a surprisingly high percentage of mixed tumors are identified in AP 
versus NAP counties in women under the age of 50 years (11% vs. 4%, respectively). At 
least for estrogen-dependent uterine cancers, the obesity epidemic may be a contributing 
factor, as a linear decrease in age at diagnosis has been correlated with an increasing 
body mass index (BMI) over time.18 
Prolonged estrogen exposure is an established risk factor for uterine corpus 
cancer, and is related to a number of factors, including: obesity, nulliparity, late 
menarche, early menopause, and exogenous estrogen or tamoxifen.17,19-22 When all 
Appalachian states are considered, KY has the highest prevalence of obesity (35.2%), and 
the seventh highest obesity rate in the U.S.3,23 Even NAP KY has a higher prevalence of 
obesity than the national average of (31.2% vs 27.4%, respectively).23 Previous 
population-based reports have linked obesity to the high rate of uterine corpus cancers in 
AP KY.24 An association between estrogen excess and mixed tumors may also be 
relevant, since they are now thought to arise from genetic mutations of a pure carcinoma 
cell line.9,12,25 
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Mixed uterine malignancy, also known as carcinosarcoma or malignant mixed 
Mullerian tumor (MMMT), is now believed to be a high-grade carcinoma that arises from 
a monoclonal cell which can dedifferentiate into a sarcomatous component.9,11,12,26,27 
Unlike Type I corpus cancers, mixed tumors are typically diagnosed in the seventh 
decade, and are disproportionately seen in NHB women and in women exposed to 
tamoxifen and pelvic radiation. Like Type I corpus cancers, a national trend of decreasing 
age at diagnosis has also been reported for mixed uterine tumors, with previous mean age 
of diagnosis in the early seventies compared to current mean age of 68.2.28 Compared to 
other uterine corpus cancers, patient outcomes are considerably worse for this high-grade 
malignancy, though reportedly similar for black and white women provided they receive 
comparable treatment.29 Over the last two decades, national trends demonstrate a 
dramatic decrease in NHW from 86% to 60%, and a concomitant increase in NHB from 
12% to 20%.27 In Kentucky, the racial distribution in AP is overwhelmingly NHW, so it 
is an unexpected finding that more mixed tumors were diagnosed in AP than NAP. 
Historically, the AP population has been non-migratory. Over the last decade, 
there has been a net AP emigration of only 1.3%, compared to a net immigration into 
NAP of 3.3%.2 The population stability of the AP region makes it an intriguing target for 
the study of hereditary and environmental exposure. Previous evaluations of cancer 
inheritance patterns in AP contributed to the discovery of Lynch syndrome. Lynch 
syndrome, also known as hereditary non-polyposis colorectal cancer syndrome 
(HNPCC), can includes uterine, as well as gastrointestinal, ovarian, hepatobiliary, and 
upper urinary tract cancers. This inherited germline mutation has alterations in several 
mismatch repair genes that result in microsatellite instability which predisposes to early 
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onset cancers. These HNPCC germline cancers are often diagnosed at a younger age 
compared to similar cancers from somatic mutation. Given the increased incidence in AP 
of Type I cancers and a shift toward younger age at diagnosis, it is conceivable that 
genetic factors have contributed to our findings. In addition, there are reports suggesting 
mixed uterine malignancies may also be associated with Lynch syndrome, specifically in 
carriers of the MSH 2 and MLH 1 mutation.30,31 There is a well-known founder 
population in AP KY with the MSH 2 mutation.32 More comprehensive genetic testing of 
women in this region may provide further insight into the association between Type I 
cancers, mixed malignancies, and hereditary syndromes.  
Disparities in uterine cancer incidence and outcomes in Kentucky, and 
specifically in AP, are not necessarily a consequence of racial disparity. As background, 
AP is known to have a high cancer prevalence and is predominantly NHW. The measured 
death rates in KY are equivalent for NHB and NHW (Death Rate Ratio = 1.01; 95% CI 
0.93-1.10).1 For this investigation, Kaplan-Meier analysis shows inferior survival for 
NHB compared to NHW women overall; however, a multivariate Cox regression survival 
analysis shows that race does not independently impact survival (HR 1.08; CI 0.94-1.2, 
p=0.24. Table 5). What is evident in KY is that NHW women are three times more likely 
to be diagnosed with Type I uterine cancer than any other race. The general population in 
AP KY is 95% NHW contrasted with 82.1% for NAP counties, which may explain why 
98.8% of Type I uterine cancers in AP counties are diagnosed in NHW women. In KY, 
non-Hispanic black women are more likely to be diagnosed with aggressive uterine cell 
types, namely Type II, sarcoma and mixed malignancies. This is consistent with national 
trends, as the U.S. incidence of uterine sarcoma for NHB women is nearly twice that of 
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NHW women.24,33,34 We observed that the percentage of NHB women diagnosed with 
sarcoma or mixed tumors throughout the state is double the percent of NHB in the KY 
study population. Given the underrepresentation of NHB women in the statewide 
population, it is not surprising that the age-adjusted cancer incidence for uterine sarcoma 
and mixed malignancies is lower in Kentucky that the United States (Table 1).  
It has been previously reported that cancer patients with Medicaid or no insurance 
compared to those privately insured present with more advanced disease, are less likely to 
receive National Comprehensive Cancer Network-compliant cancer care (including 
surgery, chemotherapy, and radiation), and experience worse outcomes.35 We observe a 
higher percentage of uninsured or Medicaid in AP versus NAP counties. Overall, women 
in KY with a uterine malignancy and private insurance have better survival than those 
with no insurance, mostly from a significant contribution in NAP KY. Conversely, 
Medicaid and Medicare are independently associated with worse outcomes in AP KY. 
4.2 Limitations 
The limitations to this investigation are inherent to any observational registry 
study. As a retrospective study, Appalachian status was only measured at the time of 
cancer diagnosis which may not reflect the whole residential history of patients. Central 
pathology review is also not possible, and standard treatment or histologic interpretation 
may have changed over the study period affecting observed outcomes. In addition, KCR 
does not collect weight or BMI data for cancer patients so we are unable to validate 
previous studies that demonstrated a relationship between obesity and endometrial cancer 
in Kentucky.20,23 Lastly, while the identified correlations are significant, a causal 
 30 
 
relationship cannot be determined because of the retrospective study design. The 
strengths of this investigation include the large study population identified using SEER 
and KCR databases, and the novel and robust comparison of AP and NAP regions that 
includes several variables relevant to disease incidence and survival.   
4.3 Conclusion  
Kentucky is split into 2 distinct geographic regions, Appalachia and non-Appalachia. AP 
KY has a higher age-adjusted incidence of Type I and mixed uterine corpus cancers 
compared to NAP KY, and these cancers are being identified at a significantly younger 
age. In addition to obesity which has previously been reported, we identify several 
predisposing and inter-related socioeconomic factors that may influence uterine corpus 
cancers, including cigarette smoking, type of insurance, and possible hereditary 
syndromes (HNPCC). AP and NAP cohorts have a similar survival comparable to 
survival at the national level. While Type I corpus cancer is the most prevalent 
malignancy in KY, it is also associated with the best clinical outcomes. As the cost of 
testing decreases, a comprehensive population-based genetic study of Appalachia would 
help determine the impact of hereditary syndromes on the observed increased incidence 
and younger age at diagnosis for both Type I and mixed uterine corpus malignancies. 
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